ADL 5747

Drug Profile

ADL 5747

Alternative Names: ADL-5747; PF-04856881; PF-4856881; PF-4856881 Adolor

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adolor Corporation
  • Developer Adolor Corporation; Pfizer
  • Class
  • Mechanism of Action Opioid delta receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 18 Jun 2010 Efficacy and adverse events data from a phase IIa trial in Inflammatory pain (osteoarthritis of knee) released by (Adolor Corporation)
  • 27 Jan 2010 Adolor and Pfizer initiate a phase II trial in Pain due to postherpetic neuralgia in USA
  • 30 Oct 2009 Phase-II clinical trials in Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top